Skip to main content
DIRUI INDUSTRIAL CO.,LTD. logo

DIRUI INDUSTRIAL CO.,LTD. — Investor Relations & Filings

Ticker · 300396 ISIN · CNE100001XS7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,689 across all filing types
Latest filing 2023-04-17 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300396

About DIRUI INDUSTRIAL CO.,LTD.

https://www.dirui.com.cn

DIRUI INDUSTRIAL CO.,LTD. specializes in the research, development, manufacturing, and distribution of medical laboratory instruments and diagnostic reagents. The company provides comprehensive solutions for in-vitro diagnostics (IVD), focusing on several key clinical areas including urinalysis, biochemistry, hematology, and chemiluminescence immunoassay. Its product portfolio features high-throughput automated analyzers and integrated laboratory systems designed to enhance diagnostic efficiency and accuracy. DIRUI serves a global market, providing medical institutions and laboratories with a wide range of diagnostic tools, from urine sediment analysis to vaginal secretion testing. The company emphasizes technological innovation and quality control to support clinical decision-making and patient care through reliable laboratory automation and standardized testing protocols.

Recent filings

Filing Released Lang Actions
2022年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2022 by 迪瑞医疗科技股份有限公司. It discusses the company's internal control evaluation, including financial and non-financial control defect assessments, internal audit, control environment, risk assessment, and compliance with regulatory standards. The document is detailed and contains substantive content about internal control effectiveness and related procedures, not just an announcement or summary. It is not a full annual report (10-K), earnings release, or other financial statement report but rather a specialized report on internal control evaluation. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and internal control evaluations. The document length (8198 characters) and detailed content support this classification with high confidence. FY 2022
2023-04-17 Chinese
关于2021年限制性股票激励计划调整回购价格并回购注销部分限制性股票的公告
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement regarding the adjustment of the repurchase price and the repurchase and cancellation of restricted stocks under the 2021 restricted stock incentive plan of the company. It includes specifics about the number of shares repurchased, the price adjustments based on dividend distributions, approvals from board and supervisory meetings, independent directors' opinions, and legal opinions. The document is not a full financial report, earnings release, or management discussion but rather a formal announcement about share repurchase and cancellation related to stock incentives. This fits the category of Transaction in Own Shares (POS), which covers company buybacks or cancellations of its own shares. The document length and detail confirm it is not a brief announcement or a simple notice but a full disclosure of a share repurchase transaction.
2023-04-17 Chinese
独立董事述职报告（余宇莹）
Board/Management Information Classification · 95% confidence The document is titled as the "2022年度独立董事述职报告" which translates to "2022 Annual Independent Director's Work Report". It details the independent director's attendance at board meetings, opinions on various company matters, committee work, and efforts to protect investor rights during the year 2022. The content focuses on governance, oversight, and the independent director's role rather than financial results or audit opinions. It is a report by a board member about their duties and activities, which fits the category of Board/Management Information (MANG). The document length is 3615 characters, which is relatively short but contains substantive content about board activities, not just an announcement. Therefore, it is not a report publication announcement or regulatory filing. It is not an audit report, annual report, or earnings release. Hence, the best classification is MANG with high confidence.
2023-04-17 Chinese
2022年度非经营性资金占用及其他关联资金往来情况专项报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项报告" (special report) concerning non-operating fund occupation and other related party fund transactions for the year 2022 of Dirui Medical Technology Co., Ltd. It includes detailed tables summarizing non-operating fund occupation and related party transactions, with references to audited financial statements and regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The document is signed by certified public accountants and approved by the board on April 14, 2023. It is a standalone audit-related report focusing on specific financial compliance and related party transactions, not a full annual report or earnings release. The content and format align with an Audit Report / Information filing rather than a full Annual Report or other categories. The document length is under 5,000 characters but contains substantive financial data and audit conclusions, so it is not merely an announcement. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2022
2023-04-17 Chinese
2022年度财务决算报告
Annual Report Classification · 95% confidence The document is titled as the "2022 年度财务决算报告" which translates to "2022 Annual Financial Settlement Report". It contains detailed financial statements including balance sheets, income statements, cash flow statements, and notes for the full fiscal year ending December 31, 2022. The report includes audited financial data with an unqualified audit opinion from a certified accounting firm. The content covers comprehensive financial performance, financial position, cash flows, and detailed analysis of changes compared to the prior year. The length of the document (6257 characters) and the depth of financial data confirm it is a full annual financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2022
2023-04-17 Chinese
关于2022年日常关联交易确认及2023年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the confirmation of daily related party transactions for the year 2022 and the forecast of such transactions for 2023 by Dirui Medical Technology Co., Ltd. It includes detailed descriptions of related party transactions, pricing principles, amounts, and independent directors' opinions on these transactions. The document is a formal disclosure to shareholders and the market about related party transactions, their compliance with regulations, and their impact on the company. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or interim reports. It is not a report itself but an announcement about related party transactions and their approval by the board and independent directors. This type of document fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2023-04-17 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.